Pre-made Ianalumab benchmark antibody ( Whole mAb, anti-TNFRSF13C therapeutic antibody, Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ianalumab biosimilar, Whole mAb, Anti-TNFRSF13C Antibody: Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ianalumab (INN; development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis.
| Products Name (INN Index) | Pre-Made Ianalumab biosimilar, Whole mAb, Anti-TNFRSF13C Antibody: Anti-BAFF-R/BAFFR/BROMIX/CD268/CVID4/prolixin therapeutic antibody |
|---|---|
| INN Name | Ianalumab |
| Target | TNFRSF13C |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | H. Lee Moffitt Cancer Center and Research Institute,MorphoSys,Novartis |
| Conditions Approved | NA |
| Conditions Active | Autoimmune hepatitis,Idiopathic pulmonary fibrosis,Multiple sclerosis,Pemphigus vulgaris,Rheumatoid arthritis,Sjogren's syndrome,Systemic lupus erythematosus,Chronic lymphocytic leukaemia |
| Conditions Discontinued | NA |
| Development Tech | POTELLIGENT Technology |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF13C |
| Package |
